Development of Zoledronic Acid-Based Nanoassemblies for Bone-Targeted Anticancer Therapy.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Bone metastasis significantly reduces cancer patient survival and quality of life.
• Current chemotherapy treatments for bone metastasis cause severe systemic toxicities.
• There is a critical need for effective bone-directed therapies.

Purpose of the Study:

• To develop and characterize novel bone-targeted nanoparticles for cancer metastasis treatment.
• To evaluate the efficacy of these nanoparticles in delivering zoledronic acid to cancer cells.
• To assess the potential of these nanoparticles in combination with chemotherapy.

Main Methods:

• Synthesis and characterization of poly(vinylpyrrolidone) and tannic acid core nanoparticles (PVT NPs) self-assembled with zoledronic acid (ZA@PVT NPs).
• In vitro assessment of nanoparticle binding, internalization, and anti-proliferative effects on prostate and breast cancer cells.
• Ex vivo evaluation of nanoparticle bone targeting in mouse models and prostate tumor tissues.
• Investigation of nanoparticle-induced chemo sensitization to docetaxel.

Main Results:

• ZA@PVT NPs were successfully constructed and characterized.
• Optimized ZA@PVT NPs demonstrated enhanced binding and internalization in metastatic cancer cells.
• ZA@PVT NPs efficiently delivered zoledronic acid, inhibiting cancer cell proliferation and targeting bone.
• ZA@PVT NPs showed selective bone targeting, sparing vital organs, and potentiated docetaxel efficacy.

Conclusions:

• ZA-based, bone-targeted nanoparticles represent a promising strategy for treating bone metastasis.
• This novel nanoparticle formulation offers improved drug delivery and reduced systemic toxicity.
• ZA@PVT NPs have significant potential for future clinical applications in managing cancer bone metastasis.